Ernexa Therapeutics (ERNAW) Liabilities and Shareholders Equity (2010 - 2026)

Ernexa Therapeutics has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 108.4% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $30.1 million (down 53.31% YoY), and the FY2025 full-year result was $5.8 million, up 10.72% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $10.5 million, up from $5.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $52.2 million in Q3 2023, with the low at $5.1 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $24.3 million across 5 years, with a median of $20.9 million in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 228.68% — and 2025, when it plunged 89.81%.
• Ernexa Therapeutics' Liabilities and Shareholders Equity stood at $22.3 million in 2022, then surged by 120.53% to $49.1 million in 2023, then slumped by 89.28% to $5.3 million in 2024, then grew by 10.72% to $5.8 million in 2025, then soared by 80.72% to $10.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $10.5 million (Q1 2026), $5.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.